COCP — Cocrystal Pharma Share News
0.000.00%
Last trade - 00:00Cocrystal Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cocrystal Pharma FY Net Income USD -17.984 Million
Cocrystal Pharma Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Cocrystal Pharma says Gave Notice To Kansas State University Research Foundation Of Election To Terminate License Agreements
Brief: Cocrystal Pharma Got Notice From Merck Sharp & Dohme Of Election To Terminate Agreement
Brief: Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
Brief: Cocrystal Pharma Q3 Net Income USD -4.165 Million
Brief: Cocrystal Pharma -Receipt Of Authorization To Initiate Phase 2A Human Challenge Trial In U.K. For CC-42344 Product Candidate
Brief: Cocrystal Pharma Doses First Subjects In Clinical Study Of Cdi-988 For Pandemic Norovirus And Coronavirus
Cocrystal Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cocrystal Pharma Q2 Net Income USD -5.026 Million
Cocrystal Pharma Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 As Norovirus Lead
Brief: Cocrystal Pharma Entered Into At-Market Offering Agreement
Brief: Cocrystal Pharma Receives Hrec Approval To Initiate Phase 1 Study To Evaluate Oral Broad-Spectrum Coronavirus 3Cl Protease Inhibitor Cdi-988
Cocrystal Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cocrystal Pharma Reports First Quarter 2023 Financial Results And Provides Updates On Its Antiviral Drug Development Programs
Brief: Cocrystal Pharma Inc Files For Mixed Shelf Of Up To $150 Million - SEC Filing
Cocrystal Pharma Inc expected to post a loss of 59 cents a share - Earnings Preview